Efficacy and Safety of Pyronaridine-artesunate for the Treatment in Uncomplicated Falciparum Malaria

• Sponsor: University of Oxford (Other)
• Overall Status: Completed
• CT.gov ID: NCT02389439
• Collaborator: NCHADS - Ministry of Health of Cambodia (Other)
• Enrollment: 123
• Locations: 3
• Arm: 1
• Actual Duration (Months): 15
• Patients Per Site: 41
• Patients Per Site Per Month: 2.7

Study Details

Study Description

Brief Summary

This study is a prospective, single arm, open-labelled clinical trial. The total number subjects will be 145 patients to receive Pyronaridine-artesunate once daily for 3 days. Dosing will be according to the body weight.

All patients will have a blood smear examined daily during the first week by microscopy until parasite clearance (2 consecutive negative slides on two consecutive days; both asexual and sexual stages). A negative blood slide will be defined as parasite count negative per 1000 WBC in two consecutive days. The sample on day 3 will be taken as close as possible to 72h after the initial blood smear.

Participant will follow up for 42 days to assess the drug efficacy and safety (Day 7, 14, 21, 28, 35 and 42).

Condition or Disease	Intervention/Treatment	Phase
Malaria, Falciparum	Drug: Pyronaridine-artesunate	Phase 2

Study Design

• Study Type: Interventional
• Actual Enrollment: 123 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Monitoring and Evaluation of the Therapeutic Efficacy and Safety of Pyronaridine-artesunate for the Treatment of Uncomplicated Falciparum Malaria in Western Cambodia, an Area of Artemisinin-resistant Falciparum Malaria
• Actual Study Start Date: Mar 1, 2015
• Actual Primary Completion Date: Dec 1, 2015
• Actual Study Completion Date: Jun 1, 2016

Arms and Interventions

Arm

Intervention/Treatment

Experimental: Pyronaridine-artesunate Pyronaridine-artesunate (Pyramax®, Shin Poong Pharmaceuticals). One tablet contains 60mg artesunate+ 180mg pyronaridine. Dosing will be according to body weight. It will be taken orally with water, once daily for 3 days. Each dose will be administered under the supervision. A dose will be repeated in full if vomiting occurs within 30 minutes of administration of the first day of administration only. 20 - < 24 kg = 1 tab 24 - < 45 kg = 2 tabs 45 - < 65 kg = 3 tabs 65 and above = 4 tabs

Drug: Pyronaridine-artesunate; Other Names: Pyramax

Outcome Measures

Primary Outcome Measures

1. result of PCR [42 day]

Secondary Outcome Measures

1. hepatic biological values [at day 0, 3,7 and day 28]

   the hepatic biological values will be measured which are AST,ALT,albumin and total bilirubin

2. eosinophil count [at day 0, 3, 7 and day 28]

3. K13 and pfmdr1 of P falciparum resistance [at day 0, 3, 7 and day 28]

4. numbers of patients with a positive malaria slide 72 hours after treatment initiation [72 hours]

5. fever clearance time [24 hours]

   the time taken for tympanic temperature to fall below 37.5˚C and remain there for at least 24 hours

6. Number of patient with reinfection and recrudescences [over 42 days]

7. PCR uncorrected ACPR [at 28 days or 42 days]

   PCR uncorrected ACPR at 28 days or 42 days for P. falciparum, P. falciparum and mixed infections in Pailin

8. PCR corrected ACPR [at 28 days and 42 days]

   PCR corrected ACPR at 28 days or for P. falciparum, P. vivax and mixed infections and at 42 days for P. falciparum and mixed infections

9. Gametocyte carriage rates [at day 0, 3, 7 day 28]

10. gametocyte clearance times [at day 0, 3, 7 and day28]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 7 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

• Adults and children ≥ 20 kg

• Symptomatic of malaria infection, i.e. history of fever within 24 hours and/or presence of fever >37.5°c.

• Microscopic confirmation of asexual stages of P. falciparum (P. falciparum and mixed infection in Pailin only)

• Capability of taking an oral medication

• Written informed consent given to participate in the trial

• Willingness and ability to adhere to follow-up visit schedule

Exclusion Criteria:

• Pregnancy or lactation (urine test for β HCG to be performed on any woman of child bearing age, that is 18 to 45 y/o)

• Female aged 12-18y

• Parasitemia > 150 000/µL).

• Signs or symptoms indicative of severe malaria:

• Impaired consciousness (Blantyre Coma Score <5)

• Severe anaemia (Hct<15%)

• Bleeding disorder -evidenced by epistaxis, bleeding gums, frank haematuria, bleeding from venepuncture sites

• Respiratory distress

• Severe jaundice

• Known hypersensitivity to artemisinins - defined as history of erythroderma/other severe cutaneous reaction, angioedema or to pyronaridine

• History of splenectomy

• Known history or evidence of clinically significant disorders, such as:

• Known active Hepatitis A, e.g. by detection of anti HAV-IgM.

• Known hepatitis B surface antigen (HBsAg) carrier.

• Known hepatitis C antibody (HCV Ab).

• Liver function tests (AST/ALT levels) more than 2.5 times the upper limit of normal range.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Tasanh Health Centre, Battambang	Battambang		Cambodia
2	Referral hospital (Pailin)	Pailin		Cambodia
3	Promoy Health Centre (Pursat)	Pursat)		Cambodia

Sponsors and Collaborators

• University of Oxford
• NCHADS - Ministry of Health of Cambodia

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: University of Oxford
• ClinicalTrials.gov Identifier: NCT02389439
• Other Study ID Numbers: Cambodia1
• First Posted: Mar 17, 2015
• Last Update Posted: Sep 20, 2018
• Last Verified: Apr 1, 2015

• Additional relevant MeSH terms: Malaria; Malaria, Falciparum; Artesunate; Pyronaridine

Study Results

No Results Posted as of Sep 20, 2018